Compare AHT & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHT | PASG |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | 116 | 27 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 19.2M |
| IPO Year | N/A | 2020 |
| Metric | AHT | PASG |
|---|---|---|
| Price | $3.23 | $4.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 55.9K | ★ 93.8K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.36 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $3.29 |
| 52 Week High | $6.93 | $20.00 |
| Indicator | AHT | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 57.13 | 45.65 |
| Support Level | $3.07 | $3.94 |
| Resistance Level | $4.67 | $5.06 |
| Average True Range (ATR) | 0.09 | 0.33 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 78.58 | 62.96 |
Ashford Hospitality Trust Inc is a real estate investment trust (REIT) operating in the hotel lodging industry. The company's portfolio consists of upscale and upper upscale full-service hotels, with its investment focused on acquiring and investing in upper upscale full-service hotels in the United States that have revenue per available room (RevPAR) generally less than twice the U.S. national average, through direct real estate ownership as well as equity and debt investments. Its hotel properties are mainly branded under internationally recognized names such as Hilton, Hyatt, Marriott, and InterContinental Hotels Group. It operates through a single reportable business segment, direct hotel investments, which involves owning hotel properties through acquisitions or new development.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.